BSEM Keeps Doing What Most MedTech Can’t — Profit

Will this outgrow the OTC? ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  

You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. This message is from Huge Alerts.   IS BSEM ABOUT TO OUTGROW THE OTC? PROFITABLE EXECUTION, BREAKTHROUGH CLINICAL DATA, AND A $25.50 ANALYST TARGET SUGGEST A MAJOR RE-RATE COULD BE COMING! BioStem Technologies (BSEM) continues to separate itself from the noise in MedTech by delivering real earnings power.  In Q3 2025, the company reported $2.7 million in adjusted EBITDA—its seventh straight profitable quarter—while maintaining strong margins and a solid cash position. Even with pricing pressure across the wound-care industry, BSEM's vertically integrated, GMP-compliant platform has allowed it to grow volume, protect profitability, and invest in long-term expansion. The real potential upside lies in BioStem's clinical and market momentum. BioREtain® allografts have demonstrated superior wound-closure outcomes in peer-reviewed trials, targeting a global wound-care market measured in the tens of billions.  With new access points through federal programs, state Medicaid, and hospitals—and a planned Nasdaq uplisting in 2026—BSEM is building the foundation for institutional adoption and accelerated growth. Analysts are already taking notice with a $25.50 price target that implies meaningful upside from current levels. Discover why BSEM is emerging as one of the most compelling profitable MedTech stories in 2026 We are issuing this disclosure in compliance with Section 17(b) of the Securities Act, which requires us to disclose any compensation received or expected to be received in cash or in kind in connection with the purchase or sale of any security. We would like to inform you that we have received or expect to receive compensation in connection with the purchase or sale of the securities of BioStem Technologies Inc. (OTC: BSEM) . The compensation consists of up to $6,500 and was received/will be received from Sideways Frequency. This compensation should not be considered as an endorsement of the securities of BioStem Technologies Inc. (OTC: BSEM) and we are not responsible for any errors or omissions in any information provided about the securities of BioStem Technologies Inc. (OTC: BSEM) by Huge Alerts. We encourage you to conduct your own due diligence and research before making any investment decisions. You should also consult with a financial advisor before making any investment decisions. This disclosure is made as of 01/16/2026. Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our Privacy Policy or our Legal Notices. Behind the Markets You are receiving this email because you are subscribed to Morning Watchlist from Behind the Markets. If you no longer wish to receive these partner emails, please unsubscribe here. Today's Bonus Content: [Revealed] The $100 Starlink Pre-IPO Jackpot!